Immunome (NASDAQ:IMNM – Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.61) by ($0.15), FiscalAI reports.
Immunome Stock Performance
NASDAQ IMNM opened at $19.36 on Tuesday. The stock has a 50 day moving average price of $21.33 and a 200-day moving average price of $22.37. Immunome has a one year low of $15.46 and a one year high of $30.06. The company has a market capitalization of $2.20 billion, a P/E ratio of -7.65 and a beta of 2.68.
Analyst Ratings Changes
IMNM has been the subject of a number of research reports. HC Wainwright restated a “buy” rating on shares of Immunome in a research report on Tuesday, October 27th. Piper Sandler reduced their price target on shares of Immunome from $33.00 to $30.00 and set an “overweight” rating on the stock in a report on Tuesday. Wedbush reiterated an “outperform” rating and issued a $35.00 price target on shares of Immunome in a report on Tuesday, October 27th. Alliance Global Partners initiated coverage on shares of Immunome in a research note on Monday, September 21st. They issued a “buy” rating and a $32.00 price target on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Immunome in a report on Thursday, October 15th. Fourteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $33.92.
Get Our Latest Research Report on IMNM
Insider Buying and Selling at Immunome
In other Immunome news, Director Isaac Barchas sold 11,048 shares of the stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $27.25, for a total transaction of $301,058.00. Following the completion of the transaction, the director owned 92,211 shares in the company, valued at $2,512,749.75. This trade represents a 10.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jack Higgins sold 13,200 shares of the stock in a transaction on Friday, September 11th. The shares were sold at an average price of $25.32, for a total transaction of $334,224.00. Following the transaction, the insider owned 65,050 shares of the company’s stock, valued at $1,647,066. This trade represents a 16.87% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 7.21% of the company’s stock.
About Immunome
Immunome is a biotechnology company focused on discovering and developing therapies for cancer. It uses an antibody-discovery platform to identify targets and develop medicines intended to address areas of significant unmet medical need.
The company’s research and development programs include targeted cancer treatments, such as antibody-based therapies and other drug candidates. Its portfolio has included investigational medicines for solid tumors and other cancers; these products are in development and are not necessarily approved for commercial use.
Immunome became a publicly traded company in 2023 following a merger with Morphimmune and a combination with Ayala Pharmaceuticals.
Featured Stories
- Five stocks we like better than Immunome
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.
